Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492257 | 0.87 | IDO1 (0.34) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL6479646 | 0.80 | ALDH1A1 (0.30) | ALDH1A1ESR1HSD17B10 | |
| SCHEMBL6480327 | 0.79 | FABP7 (0.35) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL6481758 | 0.77 | FABP7 (0.33) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL6492090 | 0.75 | TSHR (0.34) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL6492254 | 0.75 | TSHR (0.34) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL1196934 | 0.75 | FABP7 (0.50) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL30493000 | 0.75 | FABP7 (0.50) | TSHRKMT2AFABP7FABP5MTNR1A | |
| SCHEMBL6491871 | 0.73 | — | — | |
| SCHEMBL6480324 | 0.72 | FABP7 (0.35) | TSHRKMT2AFABP7FABP5MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 | TSHR 1124/4885KMT2A 3491/4885FABP7 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.